Drugs / BIC/FTC/TAF
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04564547 Comparator | Mar 2021 → Jan 2025 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIC/FTC/TAF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04564547 ↗ |
| Route | Oral | “BIC/FTC/TAF tablet taken by mouth.” NCT04564547 ↗ |